Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.
You may also be interested in...
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.